Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 17, Issue 7, Pages 921-936
Publisher
Informa Healthcare
Online
2016-02-02
DOI
10.1517/14656566.2016.1149164
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial
- (2016) Jeffrey A. Lieberman et al. BIOLOGICAL PSYCHIATRY
- Recent advances in the treatment of hyperammonemia
- (2015) Simon Matoori et al. ADVANCED DRUG DELIVERY REVIEWS
- Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial
- (2015) Christoph U. Correll et al. AMERICAN JOURNAL OF PSYCHIATRY
- Uncovering the Hidden Risk Architecture of the Schizophrenias: Confirmation in Three Independent Genome-Wide Association Studies
- (2015) Javier Arnedo et al. AMERICAN JOURNAL OF PSYCHIATRY
- Continuous infusion of the α7 nicotinic acetylcholine receptor agonist EVP-6124 produces no signs of tolerance at memory-enhancing doses in rats
- (2015) Nick P. van Goethem et al. BEHAVIOURAL PHARMACOLOGY
- Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Encenicline, a Selective α7 Nicotinic Receptor Partial Agonist, in Single Ascending-dose and Bioavailability Studies
- (2015) Ann J. Barbier et al. CLINICAL THERAPEUTICS
- Psychometric evaluation of the negative syndrome of schizophrenia
- (2015) Maria Paz Garcia-Portilla et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
- Oxytocin and social cognition in affective and psychotic disorders
- (2015) M. Mercedes Perez-Rodriguez et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Valbenazine granted breakthrough drug status for treating tardive dyskinesia
- (2015) Thomas Müller EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?
- (2015) Leslie Citrome et al. Expert Review of Neurotherapeutics
- The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out
- (2015) L. Citrome INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be hel
- (2015) L. Citrome INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia
- (2015) John M. Kane et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Can computer-assisted cognitive remediation improve employment and productivity outcomes of patients with severe mental illness? A meta-analysis of prospective controlled trials
- (2015) Joyce Y.C. Chan et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Social cognition, social competence, negative symptoms and social outcomes: Inter-relationships in people with schizophrenia
- (2015) Marc Kalin et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Glutamate and dopamine in schizophrenia: An update for the 21st century
- (2015) Oliver Howes et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Brexpiprazole: Another Multipurpose Antipsychotic Drug?
- (2015) Robert H. Howland JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES
- Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials
- (2015) Y Iwata et al. MOLECULAR PSYCHIATRY
- Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia
- (2015) T W Weickert et al. MOLECULAR PSYCHIATRY
- Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia
- (2015) Richard SE Keefe et al. NEUROPSYCHOPHARMACOLOGY
- ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers
- (2015) Robert E. Davis et al. PSYCHOPHARMACOLOGY
- Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia
- (2015) Richard S. E. Keefe et al. SCHIZOPHRENIA BULLETIN
- Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders
- (2015) Joey W. Trampush et al. SCHIZOPHRENIA BULLETIN
- A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia
- (2015) John M. Kane et al. SCHIZOPHRENIA RESEARCH
- The impact of clinical heterogeneity in schizophrenia on genomic analyses
- (2015) Sherri G. Liang et al. SCHIZOPHRENIA RESEARCH
- Sex hormones and oxytocin augmentation strategies in schizophrenia: A quantitative review
- (2015) Sophie M. Heringa et al. SCHIZOPHRENIA RESEARCH
- The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?
- (2015) Leslie Citrome et al. Expert Review of Neurotherapeutics
- The MATRICS Consensus Cognitive Battery: What We Know 6 Years Later
- (2014) Michael F. Green et al. AMERICAN JOURNAL OF PSYCHIATRY
- PCP-induced deficits in murine nest building activity: Employment of an ethological rodent behavior to mimic negative-like symptoms of schizophrenia
- (2014) Christian Spang Pedersen et al. BEHAVIOURAL BRAIN RESEARCH
- A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia
- (2014) AnnCatherine M Downing et al. BMC Psychiatry
- P.3.d.025 Safety and tolerability of cariprazine in long-term treatment of schizophrenia: integrated summary of safety data
- (2014) H.A. Nasrallah et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- EPA-0870 – Efficacy and safety of cariprazine in patients with acute exacerbation of schizophrenia: results of two phase III trials
- (2014) I. Laszlovszky et al. EUROPEAN PSYCHIATRY
- Emerging drugs for schizophrenia: an update
- (2014) Luisa-Sophie Köster et al. EXPERT OPINION ON EMERGING DRUGS
- Investigational drugs for anxiety in patients with schizophrenia
- (2014) Ricardo P Garay et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Unmet Needs in the Treatment of Schizophrenia
- (2014) Leslie Citrome JOURNAL OF CLINICAL PSYCHIATRY
- Humanistic burden in schizophrenia: A literature review
- (2014) A. Millier et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Recent genetic findings in schizophrenia and their therapeutic relevance
- (2014) Paul J Harrison JOURNAL OF PSYCHOPHARMACOLOGY
- Translating Human Genetics into Novel Treatment Targets for Schizophrenia
- (2014) Christian R. Schubert et al. NEURON
- Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
- (2014) Maarten Bak et al. PLoS One
- Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
- (2014) Gretchen L. Snyder et al. PSYCHOPHARMACOLOGY
- POSITIVE SYMPTOMS RESPOND TO ADD-ON ASPIRIN IN SCHIZOPHRENIA PATIENTS WITH HIGH SERA CRP LEVELS: A POST-HOC ANALYSIS OF AN RCT
- (2014) Mark Weiser et al. SCHIZOPHRENIA RESEARCH
- Poster #T94 OPTIMIZING TREATMENT AND SIGNAL DETECTION WITH EVP-6124 IN A CIAS PHASE 2B STUDY
- (2014) Dana Hilt et al. SCHIZOPHRENIA RESEARCH
- An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial
- (2014) Suresh Durgam et al. SCHIZOPHRENIA RESEARCH
- Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol
- (2014) Pelle L Ishøy et al. BMJ Open
- Comparison of self-report and performance-based measures of everyday functioning in individuals with schizophrenia: implications for measure selection
- (2014) Colette Seter Elliott et al. Cognitive Neuropsychiatry
- Bitopertin
- (2014) Donald C. Goff JAMA Psychiatry
- Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy
- (2013) Leslie Citrome ADVANCES IN THERAPY
- The Cytokine Model of Schizophrenia: Emerging Therapeutic Strategies
- (2013) Ragy R. Girgis et al. BIOLOGICAL PSYCHIATRY
- A Review of the Pharmacology, Efficacy and Tolerability of Recently Approved and Upcoming Oral Antipsychotics: An Evidence-Based Medicine Approach
- (2013) Leslie Citrome CNS DRUGS
- Defining and measuring negative symptoms of schizophrenia in clinical trials
- (2013) Stephen R. Marder et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability
- (2013) Leslie Citrome Expert Opinion on Drug Metabolism & Toxicology
- When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed
- (2013) L. Citrome et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Famotidine Augmentation in Schizophrenia: Hope or Hype?
- (2013) Chittaranjan Andrade JOURNAL OF CLINICAL PSYCHIATRY
- Memantine Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia
- (2013) Farzin Rezaei et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- A Randomized Clinical Trial of Histamine 2 Receptor Antagonism in Treatment-Resistant Schizophrenia
- (2013) Katarina Meskanen et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
- (2013) Stefan Leucht et al. LANCET
- Selective Serotonin 3 Receptor Antagonist Treatment for Schizophrenia: Meta-analysis and Systematic Review
- (2013) Taro Kishi et al. NEUROMOLECULAR MEDICINE
- Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models
- (2013) Holly Moore et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Adjunctive Use of Nonsteroidal Anti-inflammatory Drugs for Schizophrenia: A Meta-analytic Investigation of Randomized Controlled Trials
- (2013) Masahiro Nitta et al. SCHIZOPHRENIA BULLETIN
- Definition and description of schizophrenia in the DSM-5
- (2013) Rajiv Tandon et al. SCHIZOPHRENIA RESEARCH
- Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo
- (2013) Virginia L. Stauffer et al. SCHIZOPHRENIA RESEARCH
- Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy
- (2013) M J Bakermans-Kranenburg et al. Translational Psychiatry
- European licensing of maintenance treatment in schizophrenia
- (2012) Maria Isaac et al. LANCET
- Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010
- (2012) Joshua A Salomon et al. LANCET
- Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis
- (2012) Stefan Leucht et al. LANCET
- Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
- (2012) Theo Vos et al. LANCET
- Adjunctive Memantine Therapy for Cognitive Impairment in Chronic Schizophrenia: A Placebo-Controlled Pilot Study
- (2012) Jung Goo Lee et al. Psychiatry Investigation
- A Systematic Review and Meta-Analysis of Recovery in Schizophrenia
- (2012) E. Jaaskelainen et al. SCHIZOPHRENIA BULLETIN
- Lack of Evidence for the Efficacy of Memantine in Mild Alzheimer Disease
- (2011) Lon S. Schneider ARCHIVES OF NEUROLOGY
- Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trial
- (2011) Frances R. Levin et al. DRUG AND ALCOHOL DEPENDENCE
- Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia
- (2011) Judith Usall et al. JOURNAL OF CLINICAL PSYCHIATRY
- Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents
- (2011) István Gyertyán et al. NEUROCHEMISTRY INTERNATIONAL
- EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors
- (2011) Jos Prickaerts et al. NEUROPHARMACOLOGY
- Tolcapone,COMTpolymorphisms and pharmacogenomic treatment of schizophrenia
- (2011) Panos Bitsios et al. PHARMACOGENOMICS
- Differential Immediate and Sustained Memory Enhancing Effects of Alpha7 Nicotinic Receptor Agonists and Allosteric Modulators in Rats
- (2011) Morten S. Thomsen et al. PLoS One
- Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography
- (2011) Nicholas Seneca et al. PSYCHOPHARMACOLOGY
- Memantine Preferentially Blocks Extrasynaptic over Synaptic NMDA Receptor Currents in Hippocampal Autapses
- (2010) P. Xia et al. JOURNAL OF NEUROSCIENCE
- Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
- (2010) B. Kiss et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Exenatide and weight loss
- (2010) David P. Bradley et al. NUTRITION
- The FDA-NIMH-MATRICS Guidelines for Clinical Trial Design of Cognitive-Enhancing Drugs: What Do We Know 5 Years Later?
- (2010) R. W. Buchanan et al. SCHIZOPHRENIA BULLETIN
- Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
- (2010) Christine Rummel-Kluge et al. SCHIZOPHRENIA RESEARCH
- Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia
- (2010) Jean-Pierre Lindenmayer et al. SCHIZOPHRENIA RESEARCH
- Vocational, Social, and Cognitive Rehabilitation for Individuals Diagnosed With Schizophrenia: A Review of Recent Research and Trends
- (2010) Seth Kurzban et al. Current Psychiatry Reports
- Memantine
- (2009) Kate McKeage CNS DRUGS
- Tardive dyskinesia and new antipsychotics
- (2009) Christoph U Correll et al. CURRENT OPINION IN PSYCHIATRY
- Cognitive Improvement by Activation of α7 Nicotinic Acetylcholine Receptors: From Animal Models to Human Pathophysiology
- (2009) Morten Thomsen et al. CURRENT PHARMACEUTICAL DESIGN
- Improvement of Negative and Positive Symptoms in Treatment-Refractory Schizophrenia
- (2009) David de Lucena et al. JOURNAL OF CLINICAL PSYCHIATRY
- Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study
- (2009) J. Doorduin et al. JOURNAL OF NUCLEAR MEDICINE
- Substance Use Disorders in Schizophrenia--Clinical Implications of Comorbidity
- (2009) N. D. Volkow SCHIZOPHRENIA BULLETIN
- The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
- (2009) R. W. Buchanan et al. SCHIZOPHRENIA BULLETIN
- Identifying Cognitive Mechanisms Targeted for Treatment Development in Schizophrenia: An Overview of the First Meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative
- (2008) Cameron S. Carter et al. BIOLOGICAL PSYCHIATRY
- Microglia Activation in Recent-Onset Schizophrenia: A Quantitative (R)-[11C]PK11195 Positron Emission Tomography Study
- (2008) Bart N. van Berckel et al. BIOLOGICAL PSYCHIATRY
- Rare chromosomal deletions and duplications increase risk of schizophrenia
- (2008) Jennifer L. Stone et al. NATURE
- Large recurrent microdeletions associated with schizophrenia
- (2008) Hreinn Stefansson et al. NATURE
- A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia
- (2008) Jeffrey A Lieberman et al. NEUROPSYCHOPHARMACOLOGY
- Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study
- (2007) Amir Krivoy et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started